Jefferies Maintains Buy on Ultragenyx Pharmaceutical, Lowers Price Target to $28

Benzinga Newsdesk www.benzinga.com Negative 48.9%

Neg 48.9% Neu 0% Pos 0%

Jefferies analyst Maury Raycroft maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and lowers the price target from $77 to $28.